Stealth begins SBT-20's Phase I/II trial in Netherlands to treat Huntington's disease

Stealth BioTherapeutics has begun the Phase I/II CHALLENGE-HD clinical trial of SBT-20 in the Netherlands to treat patients with early stage Huntington's disease.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news